Susquehanna offers COVID-19 Antibodies
JOHNSON CITY, NY – VestraCare, an operator of high-quality nursing and rehabilitation facilities, is pleased to announce that its Susquehanna Nursing and Rehabilitation Center is now offering monoclonal antibody infusions for the treatment of high-risk Covid-19 patients.
In November 2020, the FDA (Food and Drug Administration) issued EUA (emergency use authorization) for the use of monoclonal antibodies for the treatment of high-risk patients with mild to moderate Covid-19 symptoms at risk for progression to severe illness and hospitalization. This is the same treatment that was given to the US President.
Susquehanna Nursing and Rehabilitation Center has the advanced clinical setting necessary to administer the infusions, as well as a highly skilled nursing staff and on-site medical providers. “We’re pleased to offer this advanced option for treating high-risk patients with recently diagnosed Covid-19 infections who meet the criteria,” stated Administrator Theresa A. Bulone, RN, MHA, LNHA.
The clinical team at Susquehanna has been working closely with its Medical Director Rana Ahmad, MD, their pharmacist consultant Guardian Consulting and their pharmacy to implement protocols for administration and aftercare in concert with those specified in the EUA.
The antibodies are made with proteins created in a laboratory and are designed to mimic the antibodies created in the body’s immune system to ward off the virus and fight infection. Susquehanna will receive the compounded medication from PharmScripts, their pharmacy on a per-patient basis.
Residents will receive the treatment in-house in the comfort of a familiar environment. The team at Susquehanna provides continuous monitoring in a designated area prior, during and post-infusion.
Susquehanna Nursing and Rehabilitation Center provides 24-hour skilled nursing care, subacute rehabilitation and short-term respite care. For more information, visit www.susquehannanursing.com.